Genlantis Announces Third Generation Transfection Reagent

Share Article

Genlantis, a division of Gene Therapy Systems, Inc. announced today the release of its third generation of transfection reagent (http://genlantis.com) in the company's popular GenePORTER® product line: GenePORTER® 3000 Transfection Reagent.

Genlantis, a division of Gene Therapy Systems, Inc. announced today the release of its third generation of transfection reagent (http://genlantis.com) in the company's popular GenePORTER® product line: GenePORTER® 3000 Transfection Reagent.

GenePORTER® 3000 is optimized for high transfection efficiency of plasmid DNA to a broad spectrum of cell lines and primary cells. According to company CEO, Anthony Sorge, "The GenePORTER® 3000 reagent utilizes a unique Advanced Carrier Enhancement (ACE) technology that provides a combination of high transfection efficiency, low cytotoxicity, and ease of use that is not available from competing transfection reagents on the market."

"GenePORTER® 3000 reagent's advantage is that it provides both better efficiencies and lower toxicities vs. other supplier's transfection reagents," said Sorge. "Usually, scientists face a trade-off between high transfection efficiency and low cytotoxicity. The major transfection reagents (http://www.genlantis.com) kits available today typically offer only one or the other of these two benefits. GenePORTER® 3000 reagent offers both, and at a favorable price point"

Furthermore, GenePORTER® 3000 offers the advantage of a fast "reverse-transfection" style protocol. "This will save scientists valuable time and labor on top of the better efficiency and lower toxicity," said Genlantis senior scientist, Marie Callahan.

The GenePORTER® 3000 Transfection Reagent is now available from Genlantis, and may be ordered via phone (888-428-0558), via fax (858-623-9494) or via the company's website at http://www.genlantis.com. It is also available through Genlantis' main U.S. distributor, Fisher Scientific, as well as through Genlantis' network of international distributors.

About Genlantis
Genlantis, a division of Gene Therapy Systems, Inc., provides innovative reagents and services to improve life science research. Focus areas include: transfection, RNA interference, cell culture, gene expression, and protein production.

Source: Genlantis, a division of Gene Therapy Systems, Inc.
Contact: Mike Vengrow, Technical Support Manager 858-457-1919, Ext. 6125

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Danny Shepherd

800-658-7511
Email >